Cargando…
Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis
Hypomagnesemia is a serious adverse event for patients treated with cetuximab, an inhibitor of endothelial growth factor receptor (EGFR). However, no significant association has yet been established between cetuximab and hypomagnesemia in randomized controlled clinical trials (RCTs). The present stu...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700916/ https://www.ncbi.nlm.nih.gov/pubmed/23833666 http://dx.doi.org/10.3892/ol.2013.1301 |